SPHRY Starpharma Holdings Limited Sponsored ADRs

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1/2 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:SPL.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$4.75    OTCQX
As of 07/01/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  12/29/2004
Outstanding shares:  40,844,341
Average volume:  1,150
Market cap:   $194,010,620
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy